Abstract
Pharmacogenomics promises improved outcomes through individualized prescribing. However, the lack of diversity in studies impedes clinical translation and equitable application of precision medicine. We evaluated the frequencies of PGx variants, predicted phenotypes, and medication exposures using whole genome sequencing and EHR data from nearly 100k diverse All of Us Research Program participants. We report 100% of participants carried at least one pharmacogenomics variant and nearly all (99.13%) had a predicted phenotype with prescribing recommendations. Clinical impact was high with over 20% having both an actionable phenotype and a prior exposure to an impacted medication with pharmacogenomic prescribing guidance. Importantly, we also report hundreds of alleles and predicted phenotypes that deviate from known frequencies and/or were previously unreported, including within admixed American and African ancestry groups.
Competing Interest Statement
E.V. owns shares in Codified Genomics, a provider of genetic interpretation software. All BCM-affiliated authors declare that Baylor Genetics is a BCM affiliate that derives revenue from genetic testing. All other others declared that they had no competing interests.
Funding Statement
National Institutes of Health Grant TL1 TR001858 (AH) National Institutes of Health Grant OT2 OD026554 (PE) National Institutes of Health Grant OT2 OD002748 (PE) Shear Family Foundation (AH) Myers Family Foundation (AH)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All of Us Institutional Review Board gave ethical approval for this work. An exemption to the Data and Statistics Dissemination Policy has been granted by the All of Us Research Program Resource Access Board to report counts <20.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data used in this analysis is available through the All of Us Researcher Workbench. The code is made available as a demonstration project within a featured workspace titled "Demo - Pharmacogenomics (PGx) variant frequency and medication exposures". Further, the PGx haplotype calls from both Stargazer and PharmCAT are available to all users for additional genotype-phenotype discovery and can be accessed through the featured workspace.
